By Heather Callaghan A pharma company with generic drugs meets michrochip and biotech in a marriage of implantable devices that are shockingly close to the finish line of commercialization. Deals were made. Money exchanged. Development in process – this is actually going to happen. Is this the next phase of singularity? The complete bypassing of pills, injections – things that one actively